The pharmaceutical group Pfizer recorded sales of 25.7 billion dollars (24.4 billion euros) in the first quarter, up 77% year on year, largely thanks to sales of its vaccine against Covid. -19.
The company has also maintained its forecast of selling 22 billion dollars (20.9 billion euros) of its anti-Covid pill, Paxlovid, over the whole year, according to its financial results published on Tuesday.
The World Health Organization (WHO) strongly recommended this antiviral in April for patients with less severe forms of Covid-19 and “at higher risk of hospitalization”.
Pfizer, on the other hand, revised its annual profit estimate downwards, mainly due to a change in its accounting standards.
The American stock market regulator requires pharmaceutical groups to include certain expenses, in particular for acquisitions in research and development, in their financial projections.
An annual turnover between 98 and 102 billion dollars
Forecasts for annual turnover, on the other hand, are still between 98 and 102 billion dollars (between 93 and 97 billion euros). The Cominarty vaccine against Covid-19 should represent sales of 32 billion dollars (30.4 billion euros).
From January to March, the group’s net profit reached 7.9 billion dollars.
“We are on track to deliver on our commitment to deliver at least 2 billion doses to low- and middle-income countries in 2021 and 2022, including at least 1 billion this year,” said Pfizer CEO Albert Bourla.